FDA Denies WLF Petition To Allow Dissemination Of Off-Label Information
This article was originally published in The Gray Sheet
Executive Summary
Dissemination of journal reprints representing off-label use of a device or drug will not by themselves trigger FDA enforcement action against a manufacturer, according to the agency
You may also be interested in...
FDLI Off-Label Promotion Discussion Ventures Into “Abstract” Territory
Companies should request records of FDA correspondence related to premarket notification when weighing the purchase of another firm's 510(k), attorney Jeffrey Gibbs advised during a Sept. 13-14 Food & Drug Law Institute meeting in Washington, D.C
FDLI Off-Label Promotion Discussion Ventures Into “Abstract” Territory
Companies should request records of FDA correspondence related to premarket notification when weighing the purchase of another firm's 510(k), attorney Jeffrey Gibbs advised during a Sept. 13-14 Food & Drug Law Institute meeting in Washington, D.C
WLF Answers Democrats In First Amendment Off-Label Promotion Debate
Off-label information is not "inherently misleading," and consequently FDA should ease restrictions for disseminating it, the Washington Legal Foundation asserts in its response to congressional Democrats' interpretation of First Amendment case law